Inovio Pharmaceuticals
99 hedge funds and large institutions have $48.4M invested in Inovio Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 27 reducing their positions, and 28 closing their positions.
2,155% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $111K
134% more capital invested
Capital invested by funds: $20.7M → $48.4M (+$27.8M)
11.25% more ownership
Funds ownership: 27.73% → 38.97% (+11%)
4% less funds holding
Funds holding: 103 → 99 (-4)
14% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 28
19% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$6.56M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$6.25M |
| 3 |
BCM
Boxer Capital Management
San Diego,
California
|
+$4.4M |
| 4 |
Millennium Management
New York
|
+$3.11M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$4.03M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$1.21M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$349K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$300K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$192K |
INO Hedge Fund Activity: Q3 2025 in Review
99 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2025, worth a combined $48.4M — up 134% from $20.7M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of INO and 24 opened new positions — a net loss of 4 holders — while 27 trimmed existing stakes and 22 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $6.56M. The largest seller was Deep Track Capital, exiting entirely with an estimated $4.03M sold.
- 99 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2025, down from 103 in Q2 2025.
- Funds reported $48.4M of Inovio Pharmaceuticals stock for Q3 2025, up 134% quarter-over-quarter.
- 24 funds opened new Inovio Pharmaceuticals positions in Q3 2025 and 28 closed out, a net change of -4 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2025 was Adage Capital Partners, an estimated $6.56M added.
- The largest Inovio Pharmaceuticals seller in Q3 2025 was Deep Track Capital, an estimated $4.03M sold.
Based on aggregated 13F filings for Q3 2025.